BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. - Wikidata - awgldk - TriplyDB

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

http://www.wikidata.org/entity/Q39596672

about

Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1 Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies Growth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cells Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.Therapeutic modulators of STAT signalling for human diseases A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.CD44 targets Wnt/β-catenin pathway to mediate the proliferation of K562 cells Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.New insights into antigen specific immunotherapy for chronic myeloid leukemia The exploration of network motifs as potential drug targets from post-translational regulatory networks KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study.Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.Targeting the mTOR Pathway in Leukemia.Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib.Addressing intra-tumoral heterogeneity and therapy resistance.Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.Chromothripsis in Hodgkin lymphoma.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.LncRNA SNHG5 regulates imatinib resistance in chronic myeloid leukemia via acting as a CeRNA against MiR-205-5p.Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients.

P2860

Q21198862-80B70657-92A0-4E2E-80C9-6BC93CCE400C Q28540799-D67ED692-E813-44BF-BEC1-587A660C7C11 Q28830045-FAEDA1E6-CC51-4E2F-AA2B-6898FEB10AAA Q33558141-D5143233-2D92-43A7-9325-895E32ABE574 Q33597756-3209ACD5-A448-4B7D-A955-E55B56122A51 Q33618407-7D34CB1E-601F-4112-A960-78BA15A65366 Q33684732-2FDF2257-C56F-4BA0-A6B2-B9B10FCA0A8E Q34170309-03A60E23-20E9-46FC-A066-877A1F639736 Q34251497-42E9C6FF-E78A-4C1E-9DA6-F30B25D0B0F3 Q34260622-950D9319-B9D7-4BDA-9FF1-BA0F5E0D0D67 Q34976801-E2ED3AC9-3E88-4A2F-A263-87A08EA64A1A Q34978247-3B8950AD-6FD0-4A9B-911E-6036271AC62C Q35071010-C62CFEB4-7BC6-4436-90AF-AE4AD8BAE244 Q35102414-ABAEE47A-6482-4B45-BB8C-5417690836CD Q35727453-16E3028E-5461-4DA0-910B-C4ED768D2E0D Q36088825-36D4EB01-D078-4D80-B67F-6492D41874F7 Q36324767-F8B4A84D-7E51-4E2F-8EFE-0D8AF9BA60D5 Q36513477-D729E81C-905B-4143-A738-3C8991FD6600 Q36555138-792C3074-8071-4340-8970-3EDD4C3BCBE9 Q36738831-B649EE72-2E59-4B26-9787-CF68696B6450 Q37073009-394C624E-CF47-48EA-A4B6-8F1442478009 Q37444876-C0EE4671-3A57-4574-A9BD-B6436D27ECA4 Q37619710-BAB6CD25-93CA-454C-85D6-E4991E19B21A Q38260343-E43D6FBA-D9D0-4BF9-95B4-B3713ACAB5A8 Q38270029-848D1125-BC39-4589-A3E9-75D185292E3A Q38723094-941293E8-7DB2-459F-9412-2DCFC4FAB83E Q38757317-58BA0E2C-4FA2-4387-8B05-541335CF0DFD Q38790630-BC02FDA2-A6B3-4A94-962C-16619F460A75 Q38818540-10E21CF2-8B6C-4874-BC1E-6C73A54730C1 Q38823179-119190E2-305B-4F9A-9EE2-65AC71B7F7AA Q38909416-4F334AB0-11BB-44F1-9AD2-602BC8EB9C62 Q39158425-F3CDF76F-01CC-421F-AD04-F0DDCD54CF9F Q39429836-26A89F7E-F20C-4E40-8F01-82F3E504E9A9 Q39434177-4A1F1D55-688B-4F2F-9AB7-DFA6DACB1E1A Q39852454-1244035D-B0D1-41CB-A5D6-AFBE84637385 Q40819847-E43B9AFF-CC8B-47AB-B49E-62E25D66E119 Q40971143-57718A27-14AF-4C62-9302-6D72962B33FE Q41547616-9FDCD8B8-7C13-430C-BD63-E742BEA5CCE6 Q41904096-9010D998-2136-4EAF-998A-1BFE1A3B52F1 Q42156766-CAF0BCAB-EF99-4BF5-A8A3-E9FDA7ABD84B

P2860

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

http://www.wikidata.org/entity/Q39596672

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@en

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@nl

type

label

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@en

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@nl

prefLabel

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@en

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@nl

P1433

Q39596672-4571CDDE-25FB-4096-B77D-94FA503C5C10

P1476

Q39596672-85472A2C-BC20-4AFB-AFEF-F69840D8DCB7

P2093

Q39596672-40609A0A-2935-401B-9FCC-C6489DFEE99F

Q39596672-642B4A04-0B3F-409F-8AB3-27AE7C0A9FCD

Q39596672-CB3C8C1A-A13C-496C-B002-F3C9A833A543

Q39596672-E048AC11-F866-4929-9787-DFC34B509622

P2860

Q39596672-15C1ACBB-310E-4977-9883-577CFEC2B184

Q39596672-190E8570-6475-4D53-BEE8-F75B330AE8E0

Q39596672-38C6AC8B-260F-4081-8233-654A62395DE9

Q39596672-396505B4-169B-4FF7-BF45-6B42D5A6C9D5

Q39596672-43BFBF21-0C4B-430D-9B8A-7F8F3E9F0336

Q39596672-48E49541-99FE-4C48-B52F-605748B94ED3

Q39596672-4D93AFC5-1339-4EE2-A3E5-05F890E5453A

Q39596672-5A85A00C-8844-4707-83E0-83DBFE857B93

Q39596672-5CEECC7D-3019-4DB4-B7C9-FC60E87F5A05

Q39596672-61A3BE26-C7F6-4782-B91F-52FC3DB5E5DC

P2888

Q39596672-6294D696-BC0B-4B94-BF82-B55AE30A7C77

P304

Q39596672-45C1A435-0740-49F3-82D1-8F5B34F21DF2

P31

Q39596672-8BB60499-82F9-4BC7-A9CF-EDCBCF6E9F62

P356

Q39596672-A1D97B82-F74A-4C3D-9FA7-C4299374C054

P478

Q39596672-247EBAA2-6005-4DA4-96A1-5DCF35C1AC0E

P50

Q39596672-F77B3ADA-02B2-44AC-9B6E-1EE88D3C60A7

P577

Q39596672-030A6B4B-1B4C-4CC1-ABC2-FDB2EF82C9E6

P5875

Q39596672-5FEFDF08-8C27-4EC8-849F-0A2C9209DAF3

P6179

Q39596672-32EEB5C9-7363-49B9-8170-1A44D91E851F

P698

Q39596672-F4CD2125-170B-422C-BE49-53F5E4461A45

P932

Q39596672-4795D5C5-650E-4DCA-AC99-58E7DAFF1EE8

P356

P1433

Journal of Hematology & Oncology

P1476

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.

@en

P2093

Hilmar Quentmeier

http://www.w3.org/2001/XMLSchema#string

Julia Romani

http://www.w3.org/2001/XMLSchema#string

Margarete Zaborski

http://www.w3.org/2001/XMLSchema#string

Sonja Eberth

http://www.w3.org/2001/XMLSchema#string

P2860

High frequency of mutations of the PIK3CA gene in human cancers

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

An expanding role for mTOR in cancer

Ras oncogenes: split personalities

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Active transport of imatinib into and out of cells: implications for drug resistance.

Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-8722-4-6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Hans Guenter Drexler

P577

2011-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49816073

http://www.w3.org/2001/XMLSchema#string

P6179

1041472544

http://www.w3.org/2001/XMLSchema#string

P698

21299849

http://www.w3.org/2001/XMLSchema#string

P932

3041785

http://www.w3.org/2001/XMLSchema#string